# US 8,785,605 B2 · Humanized IL-25 antibodies > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 8,785,605 B2 - Document ID: US8785605B2 - Status: Granted - Kind: B2 - Application number: 13/075,241 - Filed: 2011-03-30 - Published: 2011-12-29 - Granted: 2014-07-22 - Earliest claimed: 2010-03-30 - Assignees: Janssen Biotech, Inc. - Applicants: Juan Carlos Almagro; Patrick Branigan; Colleen Kane; William Strohl; Susann Taudte; Mark Tornetta; John Wheeler - Inventors: Juan Carlos Almagro; Patrick Branigan; Colleen Kane; William Strohl; Susann Taudte; Mark Tornetta; John Wheeler - Web page: https://patentgrep.com/patent/US8785605B2 ## CPC - C07K 16/244: {Interleukins [IL]} - A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system - A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants - A61P 11/06: Antiasthmatics - A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] - C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered - C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity - C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues - C07K 2317/55: Fab or Fab' - C07K 2317/565: Complementarity determining region [CDR] - C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding - C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract The present invention relates to target binding members (e.g., antibodies) that bind a specified epitope of human IL-25. The invention also relates to target binding members (e.g., antibodies) that comprise one or more humanized antibody VL domain sequences and bind IL-25. The invention further relates to compositions comprising target binding members (e.g., antibodies) that bind IL-25, methods of producing such target binding members, and uses of such target binding members for the treatment or prevention of diseases and conditions (e.g., asthma, inflammatory bowel disease). ## Claims ### Claim 1 An isolated target binding member that binds IL-25, wherein the target binding comprises an antibody light chain variable region (VL) domain comprising a CDR1 having the amino acid sequence SASQGISNYLN (SEQ ID NO:6) and a CDR2 having the amino acid sequence YTSSLHS (SEQ ID NO:7) and a CDR3 having the amino acid sequence QQYLAFPYTF (SEQ ID NO:8) and an antibody heavy chain variable region (VH) domain comprising a CDR1 having the amino acid sequence GYTMN (SEQ ID NO:10), a CDR2having the amino acid sequence LINPYNGGTSYNQNFKG (SEQ ID NO:11) and a CDR3 having the amino acid sequence EDYDGYLYFAMDY (SEQ ID NO:12). ### Claim 2 (depends on 1) The target binding member of claim 1, wherein the target binding member binds amino acid residues 56-63 of SEQ ID NO:17 and amino acid residues 66-74 of SEQ ID NO:17. ### Claim 3 (depends on 1) The target binding member of claim 1, wherein the target binding member binds one or more amino acid sequences selected from the group consisting of amino acid residues 46-63 of SEQ ID NO:17 or amino acid residues 66-84 of SEQ ID NO:17. ### Claim 4 (depends on 1) The isolated target binding member of claim 1, wherein the VL domain comprises amino acid residues 1-107 of SEQ ID NO:5. ### Claim 5 (depends on 1) The isolated target binding member of claim 1, wherein the VH domain comprises amino acid residues 1-122 of SEQ ID NO:9. ### Claim 6 (depends on 1) The isolated target binding member of claim 1, wherein the target binding member comprises an antibody constant region. ### Claim 7 (depends on 6) The isolated target binding member of claim 6, wherein the antibody constant region is an IgG1 constant region or an IgG4 constant region. ### Claim 8 (depends on 7) The isolated target binding member of claim 7, wherein the target binding member comprises a whole antibody. ### Claim 9 (depends on 1) The isolated target binding member of claim 1, wherein the target binding member comprises an antibody fragment selected from the group consisting of a Fab antibody fragment, a F(ab')2 antibody fragment, and an scFv antibody fragment. ### Claim 10 (depends on 1) A composition comprising the isolated target binding member of claim 1 and a pharmaceutically acceptable carrier. ### Claim 11 (depends on 10) The composition of claim 10, wherein the composition comprises a lyophilized powder. ### Claim 12 (depends on 1) The isolated target binding member of claim 1, wherein the target binding member has a binding affinity for human IL-25 that is less than or equal to about 50 pM. ### Claim 13 (depends on 1) The isolated target binding member of claim 1, wherein the target binding member comprises a humanized antibody.